Welcome to our dedicated page for Mustang Bio SEC filings (Ticker: MBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding a biotech 10-K can feel like lab work—dense jargon on CAR-T trials, licensing deals and cash burn hides the signals you need. If you searched for “Mustang Bio SEC filings explained simply,” you’re in the right place. Stock Titan’s AI-powered summaries scan every Mustang Bio disclosure the moment it hits EDGAR, turning technical language into clear takeaways so you spend minutes—not hours—understanding Mustang Bio SEC documents with AI.
Watching insider sentiment? This hub streams Mustang Bio insider trading Form 4 transactions and pushes Mustang Bio Form 4 insider transactions real-time alerts, spotlighting when executives load up on shares ahead of pivotal data. For day-to-day fundamentals, each Mustang Bio quarterly earnings report 10-Q filing is distilled into key tables, while the Mustang Bio annual report 10-K simplified highlights runway, R&D spend and trial timelines. Layer on our Mustang Bio earnings report filing analysis to compare quarter-over-quarter cash usage and model dilution risk with ease.
Catalysts rarely wait for quarter-end, so Mustang Bio 8-K material events explained appear here within minutes—be it an FDA clearance, equity raise or new collaboration. Planning your proxy vote? The Mustang Bio proxy statement executive compensation section comes with concise AI notes detailing option grants and performance metrics. From executive stock transactions Form 4 to 10-Q footnotes, every filing type is covered, updated in real time and paired with expert analysis. Track the science and the numbers without sifting through 300 pages of biotech legalese.
The Reporting Persons—Intracoastal Capital LLC together with Mitchell P. Kopin and Daniel B. Asher—report beneficial ownership of 185,527 Mustang Bio common shares, representing 4.99% of the company’s common stock. That amount reflects shares issuable upon exercise of a warrant held by Intracoastal and is reported as shared voting and dispositive power with no sole voting or dispositive power.
The filing discloses that two warrants contain blocker provisions preventing exercise to the extent ownership would exceed 4.99%, and states that without those blockers the Reporting Persons may be deemed to beneficially own 1,328,904 shares. The Reporting Persons certify the securities were not acquired to change or influence control of the issuer.
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on CAR T and oncolytic virus therapies. For the quarter ended June 30, 2025, the company reported cash and cash equivalents of $12.7 million and total assets of $13.0 million, funded largely by equity financings. Total liabilities were $10.2 million and stockholders' equity improved to $2.9 million from a deficit of $3.9 million at year-end 2024.
Operating results show a substantially reduced loss compared with prior-year periods: net loss was $762,000 for the quarter and $915,000 for the six months ended June 30, 2025, versus significantly larger losses in 2024. The company generated approximately $6.8 million net proceeds from a February 2025 equity offering and ~$0.6 million from ATM sales during the period; subsequent July 2025 warrant exercises raised ~$7.1 million.
Management discloses substantial doubt about the company's ability to continue as a going concern and states additional financing will be required to advance clinical programs.
FAQ
What is the current stock price of Mustang Bio (MBIO)?
What is the market cap of Mustang Bio (MBIO)?
